BioSpace News Archive

SAFER™ Sample Kit offers accessible, non-invasive, and safe sample collection via saliva to enable cost-effective mass testing;

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, announced that management will participate in a fireside chat at the virtual BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23rd at 11:00 a.m. ET.

As cities across the country respond to the health and economic impact of the 2019 coronavirus disease pandemic, access to accurate, local data is key to help municipal leaders rapidly design and direct responses and resources to help communities most in need to recover.

Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced the dosing of the first patient enrolled in the Phase 2 dose expansion stage of the cavrotolimod Phase 1b/2 clinical trial.

Sigilon Therapeutics, Inc., a biotechnology company developing functional cures for patients with chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Kavita Patel, M.D., to its Board of Directors. Dr. Patel, a practicing physician, has been a leading voice in health policy development and patient-centered care and delivery systems. “As a recognized leader in cutti

Strategic partnership agreement provides Neurocrine Biosciences exclusive worldwide rights to early-to-mid-stage psychiatry pipeline compounds within Takeda’s Neuroscience portfolio

SpectronRx announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the HymonTMSARS-CoV-2 Test Kit, featuring specific clinical benefits.

Vyome Therapeutics, a clinical-stage company developing locally-acting, next generation therapeutics for immuno-inflammatory diseases, today announced positive data from its Phase 2 trial of VB-1953, a first-in-class topical bactericidal and TLR-MD2 inhibitor being developed for the treatment of moderate to severe inflammatory facial acne vulgaris. Results from the trial demonstrated a statistically significant difference in the primary endp

Second tranche of €10M from €25M growth capital loan signed with the European Investment Bank in May 2019

North American feasibility study demonstrated the utility, safety and efficacy of the alfapump in the management of patients with recurrent and refractory ascites